FONAR Corporation (NASDAQ-FONR), The Inventor of MR Scanning™, reported today its financial results for the fiscal 2021 2nd Quarter and Six Months period ended December 31, 2020. FONAR’s primary source of income and growth is attributable to its diagnostic imaging management subsidiary, Health Management Company of America (HMCA). In 2009, HMCA managed 9 MRI scanners. Currently, HMCA manages 38 MRI scanners.

Financial Results

Total Revenues-Net was $42.1 million for the six months ended December 31, 2020, as compared to $43.2 million for the corresponding six month-period ended December 31, 2019.

Total Revenues-Net for the quarter ended December 31, 2020 was $21.2 million as compared to $21.5 million for the quarter ended December 31, 2019. This also compares to $21.0 million for the preceding quarter ended September 30, 2020.

Income from Operations for the six months ended December 31, 2020 was $9.1 million as compared to $10.5 million for the corresponding six-month period ended December 31, 2019.

Income from Operations for the quarters ended December 31, 2020 and December 31, 2019 was $5.0 million. There was a 20% increase for the recent quarter as compared to $4.2 million for the preceding quarter ended September 30, 2020.

Net Income for the six months ended December 31, 2020 was $7.2 million as compared to $8.7 million for the corresponding six-month period ended December 31, 2019.

Net Income for the quarter ended December 31, 2020 was $3.9 million as compared to $4.2 million for the corresponding quarter ended December 31, 2019. There was a 22% increase for the recent quarter as compared to $3.3 million for the preceding quarter ended September 30, 2020.

Diluted Net Income per Common Share Available to Common Stockholders for the six months ended December 31, 2020 was $0.80 as compared to $0.92 for the corresponding six-month period ended December 31, 2019.

Diluted Net Income per Common Share Available to Common Stockholders for the quarters ended December 31, 2020 and December 31, 2019 was $0.44. There was a 22% increase for the recent quarter as compared to $0.36 for the preceding quarter ended September 30, 2020.

Selling, general & administrative expenses (SG&A) for the six months ended December 31, 2020 increased 27% to $10.7 million as compared to $8.5 million for the corresponding six months ended December 31, 2019. This increase was almost exclusively due to reserves of an incremental $3.9 million placed on service contracts and management fees and other receivables resulting from the COVID-19 pandemic. It is too early to know how much of these reserves will be recovered.

Selling, general & administrative expenses (SG&A) for the quarter ended December 31, 2020 increased 9% to $4.5 million, as compared to $4.2 million for the corresponding quarter ended December 31, 2019. This increase was almost exclusively due to reserves of an incremental $1.7 million placed on service contracts and management fees and other receivables resulting from the COVID-19 pandemic. It is too early to know how much of these reserves will be recovered.

Research and Development (R&D) expenses were $0.8 million for the six months ended December 31, 2020, as compared to $1.1 million for the corresponding six-month period ended December 31, 2019.

Research and Development (R&D) expenses for the quarter ended December 31, 2020 were $0.4 million as compared to $0.6 million for the quarter ended December 31, 2019.

Operating Cash Flow at December 31, 2020 decreased 6% to $9.6 million, compared with $10.2 million for the period ended December 31, 2019. For comparison, Operating Cash Flow for the year ended June 30, 2020 was $20.4 million, an increase of 5% versus $19.4 million for the previous fiscal year ended June 30, 2019.

Cash and cash equivalents and short term investments increased 10% to $40.6 million at December 31, 2020 versus $36.8 million at the fiscal year ended June 30, 2020.

Total Current Assets at December 31, 2020 were $101.6 million, as compared to $95.9 million at June 30, 2020.

Total Assets were $182.1 million at December 31, 2020 as compared to $180.3 million at June 30, 2020.

Total Current Liabilities were $16.9 million at December 31, 2020 as compared to $18.7 million at June 30, 2020.

Total Liabilities at December 31, 2020 was $50.3 million, as compared to $54.0 million at June 30, 2020.

The Total Assets / Total Liabilities ratio at December 31, 2020 was 3.6 as compared to 3.3 at June 30, 2020 .

Working Capital increased 10% to $84.7 million at December 31, 2020 versus $77.2 million at the fiscal year ended June 30, 2020.

Management Discussion

President and CEO, Timothy R. Damadian, said, “Although the COVID-19 pandemic has negatively impacted our management subsidiary, HMCA, since March of last year, we are steadily recovering.

The MRI scan volume in the quarter ending June 30, 2020 was 27,757, which was 38% lower than the scan volume in the prior quarter (45,123). The scan volume for the next quarter (the quarter ending on September 30, 2020) grew by 50% to 41,556. The scan volume for the quarter ending December 31, 2020 grew by another 7% to 44,493. In comparison to pre-pandemic scan volume a year ago (46,802 scans in the quarter ending December 31, 2019) we’re now 95% recovered. HMCA-managed facilities are located in Florida and New York. By the time both states return to normalcy, hopefully in fiscal 2021, I expect to be back to pre-pandemic scan volumes and once again on the path of steady growth.

“Prior to the pandemic,” continued Mr. Damadian, “we had planned to invest between $4 million and $6 million dollars at four (4) HMCA-managed MRI scanning centers in Fiscal 2020. We installed a second MRI scanner in the Ormond Beach, Florida facility in October, 2019, and the first MRI of what will be a two-MRI facility in Pembroke Pines, Florida in June, 2020. COVID-19 delayed the installation of a second MRI in the Islandia, New York facility until October 2020. The pandemic also delayed the installation of a second MRI in the Westchester County facility. However, I am pleased to report that it was recently installed and is currently operational in White Plains, New York, making it the 38th HMCA-managed MRI. While the execution of the plan took longer than expected, we are grateful to have all four MRIs already contributing to the growth of the company.

“With the installation of a second MRI in the White Plains facility, we now manage eleven (11) facilities with two or more MRI scanners – five (5) in New York and six (6) in Florida. Our vertical growth strategy of installing a second or even a third MRI at high-volume, high-patient-backlog facilities has been very successful. Naturally we focus on growing our remaining single-MRI facilities sites to the point where a second MRI is justified and feasible.

“As reported previously, we are planning to establish a de novo center in Bronx County, New York; we continue our search for promising locations currently underserved by FONAR’s Upright® MRI technology; and, as always, we seek to make acquisitions that would expand our existing networks of managed facilities.

Mr. Damadian concluded, “I remain grateful for the efforts of the non-controlling-interest group members of our management team. I’ve worked with them for many years. Their management skills, concern for the safety of patients and employees, and commitment to the success of FONAR and HMCA have enabled us to be profitable even in the midst of a pandemic that has been hampering our business for nearly a year.”

“Some more good news,” said Raymond V. Damadian, M.D., Chairman of the Board of FONAR Corporation, “is that the enormous appeal of the comfort and diagnostic strength that is offered by our UPRIGHT® Multi Position™ MRI, aka STAND-UP® MRI, has given the Company favorable word-of-mouth benefit. I am told by our executive team that many, or most, potential patients are already aware of this technology. So, when given the opportunity to choose, they select their MRI scans at an imaging center that features our UPRIGHT® Multi-Position™ MRI scanner.

“Physicians are also aware of the benefits of scanning the spine in the fully weight-loaded position,” continued Dr. Damadian. “Being scanned on the FONAR UPRIGHT® Multi-Position™ MRI gives them the advantage of being able to see the fully weight-loaded stress on the spine that occurs in their patient’s daily activities. Our management team spends a great deal of effort to assure that the need of the referring physician to visualize his patient’s spine in its FULL RANGE of FULLY WEIGHT-LOADED POSITIONS is a key provision. That it enables them to select the treatment that best addresses the patient's SPECIFIC physio-anatomic deficiency is our priority.

“I expect that the Company will have returned to its pre-pandemic levels of growth and profitability this year. We share the sorrow that the COVID-19 pandemic has wrought upon our society. Now with the vaccine, and other measures in place, we look forward to a rebounding economy and our own continued success.

Dr. Damadian concluded, “The Company continues its research of the imaging and quantifying of cerebrospinal fluid (CSF) flow as it circulates from the brain, down the spine and throughout the brain. We believe that this research will lead to a new understanding of the role of CSF physiology in the neurodegenerative diseases Multiple Sclerosis, Alzheimer’s, Parkinson’s, Amyotrophic Lateral Sclerosis (ALS) and childhood autism. In Fiscal 2021, the Company will continue with this valuable research made possible by the introduction of Fonar’s UPRIGHT® MRI imaging technology.”

About FONAR

FONAR, the Inventor of MR Scanning™, located in Melville, NY, was incorporated in 1978, and is the first, oldest and most experienced MRI company in the industry. FONAR introduced the world’s first commercial MRI in 1980, and went public in 1981. FONAR’s signature product is the FONAR UPRIGHT® Multi-Position™ MRI (also known as the STAND-UP® MRI), the only whole-body MRI that performs Position™ Imaging (pMRI™) and scans patients in numerous weight-bearing positions, i.e. standing, sitting, in flexion and extension, as well as the conventional lie-down position. The FONAR UPRIGHT® MRI often detects patient problems that other MRI scanners cannot because they are lie-down, ”weightless-only” scanners. The patient-friendly UPRIGHT® MRI has a near-zero patient claustrophobic rejection rate. As a FONAR customer states, “If the patient is claustrophobic in this scanner, they’ll be claustrophobic in my parking lot.” Approximately 85% of patients are scanned sitting while watching TV.

FONAR has new works-in-progress technology for visualizing and quantifying the cerebral hydraulics of the central nervous system, the flow of cerebrospinal fluid (CSF), which circulates throughout the brain and vertebral column at the rate of 32 quarts per day. This imaging and quantifying of the dynamics of this vital life-sustaining physiology of the body’s neurologic system has been made possible first by FONAR’s introduction of the MRI and now by this latest works-in-progress method for quantifying CSF in all the normal positions of the body, particularly in its upright flow against gravity. Patients with whiplash or other neck injuries are among those who will benefit from this new understanding.

FONAR’s primary source of income and growth is attributable to its wholly-owned diagnostic imaging management subsidiary, Health Management Company of America (HMCA) www.hmca.com.

FONAR’s substantial list of patents includes recent patents for its technology enabling full weight-bearing MRI imaging of all the gravity sensitive regions of the human anatomy, especially the brain, extremities and spine. It includes its newest technology for measuring the Upright cerebral hydraulics of the cerebrospinal fluid (CSF) of the central nervous system. FONAR’s UPRIGHT® Multi-Position™ MRI is the only scanner licensed under these patents.

UPRIGHT® and STAND-UP® are registered trademarks. The Inventor of MR Scanning™, CSP™, Multi-Position™, UPRIGHT RADIOLOGY™, The Proof is in the Picture™, pMRI™, CSF Videography™ and Dynamic™, are trademarks of FONAR Corporation.

This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company's financial results may be found in the company's filings with the Securities and Exchange Commission.

CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts and shares in thousands, except per share amounts) (UNAUDITED)ASSETS
         
    December 31, 2020   June 30, 2020 *
Current Assets:                
Cash and cash equivalents   $ 40,579     $ 36,802  
Short term investments     32       32  
Accounts receivable – net     4,171       4,313  
Accounts receivable - related party     72       6  
Medical receivable – net     16,373       16,172  
Management and other fees receivable – net     29,808       27,438  
Management and other fees receivable – related medical practices – net     7,262       6,896  
Inventories     1,844       1,649  
Costs and estimated earnings in excess of billings on uncompleted contracts     153       153  
Income tax receivable     —         671  
Prepaid expenses and other current assets     1,302       1,758  
                 
Total Current Assets     101,596       95,890  
                 
Accounts receivable     2,594       2,730  
Deferred income tax asset     16,848       18,810  
Property and equipment – net     21,683       21,364  
Right-of-use Asset – operating lease     29,570       31,392  
Right-of-use Asset – financing lease     1,226       1,326  
Goodwill     3,985       3,985  
Other intangible assets – net     4,014       4,109  
Other assets     632       653  
                 
Total Assets   $ 182,148     $ 180,259  

*Condensed from audited financial statements.

CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts and shares in thousands, except per share amounts) (UNAUDITED)LIABILITIES AND STOCKHOLDERS’ EQUITY
         
    December 31, 2020   June 30, 2020 *
Current Liabilities:                
Current portion of long-term debt and capital leases   $ 222     $ 108  
Accounts payable     2,198       1,965  
Other current liabilities     5,584       8,185  
Unearned revenue on service contracts     4,029       4,105  
Unearned revenue on service contracts – related party     55       —    
Operating lease liability - current portion     3,403       3,370  
Financing lease liability - current portion     200       75  
Customer deposits     1,232       855  
                 
Total Current Liabilities     16,923       18,663  
                 
Long-Term Liabilities:                
Unearned revenue on service contracts     2,528       2,656  
Deferred income tax liability     234       234  
Due to related medical practices     93       93  
Operating lease liability – net of current portion     28,415       30,105  
Financing lease liability – net of current portion     1,151       1,251  
Long-term debt and capital leases, less current portion     780       865  
Other liabilities     148       150  
                 
Total Long-Term Liabilities     33,349       35,354  
                 
 Total Liabilities     50,272       54,017  

*Condensed from audited financial statements.

CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts and shares in thousands, except per share amounts) (UNAUDITED)    LIABILITIES AND STOCKHOLDERS’ EQUITY (Continued)
         
STOCKHOLDERS' EQUITY:   December 31, 2020   June 30, 2020 *
Class A non-voting preferred stock $.0001 par value; 453 shares authorized at December 31, 2020 and June 30, 2020, 313 issued and outstanding at December 31, 2020 and June 30, 2020   $ —       $ —    
Preferred stock $.001 par value; 567 shares authorized at December 31, 2020 and June 30, 2020, issued and outstanding – none     —         —    
Common Stock $.0001 par value; 8,500 shares authorized at December 31, 2020 and June 30, 2020, 6,566 and 6,459 issued at December 31, 2020 and June 30, 2020, 6,554 and 6,447 outstanding at December 31, 2020 and June 30, 2020     1       1  
Class B Common Stock (10 votes per share) $.0001 par value; 227 shares authorized at December 31, 2020 and June 30, 2020; .146 issued and outstanding at December 31, 2020 and June 30, 2020     —         —    
Class C Common Stock (25 votes per share) $.0001 par value; 567 shares authorized at December 31, 2020 and June 30, 2020, 383 issued and outstanding at December 31, 2020 and June 30, 2020     —         —    
Paid-in capital in excess of par value     185,101       183,076  
Accumulated deficit     (50,596 )     (56,215 )
Treasury stock, at cost - 12 shares of common stock at December 31, 2020 and June 30, 2020     (675 )     (675 )
Total Fonar Corporation’s Stockholders’ Equity     133,831       126,187  
Noncontrolling interests     (1,955 )     55  
Total Stockholders' Equity     131,876       126,242  
Total Liabilities and Stockholders' Equity   $ 182,148     $ 180,259  

*Condensed from audited financial statements.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Amounts and shares in thousands, except per share amounts) (UNAUDITED)
     
    FOR THE THREE MONTHS ENDED DECEMBER 31,
REVENUES   2020   2019
Patient fee revenue – net of contractual allowances and discounts   $ 5,238     $ 5,996  
Product sales – net     3       3  
Service and repair fees – net     1,862       2,038  
Service and repair fees - related parties – net     28       28  
Management and other fees – net     11,340       10,996  
Management and other fees - related medical practices – net     2,693       2,390  
Total Revenues – Net     21,164       21,451  
COSTS AND EXPENSES                
Costs related to patient fee revenue     2,649       2,958  
Costs related to product sales     192       120  
Costs related to service and repair fees     608       772  
Costs related to service and repair fees - related parties     9       10  
Costs related to management and other fees     6,237       6,203  
Costs related to management and other fees – related medical practices     1,522       1,621  
Research and development     424       583  
Selling, general and administrative     4,541       4,163  
Total Costs and Expenses     16,182       16,430  
Income From Operations     4,982       5,021  
Interest Expense     (16 )     (19 )
Investment Income     75       139  
Income Before Provision for Income Taxes and Noncontrolling Interests     5,041       5,141  
Provision for Income Taxes     (1,113 )     (932 )
Net Income     3,928       4,209  
Net Income - Noncontrolling Interests     (817 )     (1,105 )
Net Income – Attributable to FONAR   $ 3,111     $ 3,104  
Net Income Available to Common Stockholders   $ 2,923     $ 2,914  
Net Income Available to Class A Non-Voting Preferred Stockholders   $ 140     $ 142  
Net Income Available to Class C Common Stockholders   $ 48     $ 48  
Basic Net Income Per Common Share Available to Common Stockholders   $ 0.45     $ 0.45  
Diluted Net Income Per Common Share Available to Common Stockholders   $ 0.44     $ 0.44  
Basic and Diluted Income Per Share – Class C Common   $ 0.12     $ 0.13  
Weighted Average Basic Shares Outstanding – Common Stockholders     6,465       6,447  
Weighted Average Diluted Shares Outstanding - Common Stockholders     6,593       6,575  
Weighted Average Basic and Diluted Shares Outstanding – Class C Common     383       383  

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Amounts and shares in thousands, except per share amounts) (UNAUDITED)
     
    FOR THE SIX MONTHS ENDED DECEMBER 31,
REVENUES   2020   2019
Patient fee revenue – net of contractual allowances and discounts   $ 10,330     $ 12,041  
Product sales – net     31       195  
Service and repair fees – net     3,788       4,102  
Service and repair fees - related parties – net     55       55  
Management and other fees – net     22,554       22,024  
Management and other fees - related medical practices – net     5,386       4,780  
Total Revenues – Net     42,144       43,197  
COSTS AND EXPENSES                
Costs related to patient fee revenue     5,169       5,820  
Costs related to product sales     325       450  
Costs related to service and repair fees     1,234       1,522  
Costs related to service and repair fees - related parties     18       20  
Costs related to management and other fees     11,788       12,208  
Costs related to management and other fees – related medical practices     2,950       3,157  
Research and development     824       1,055  
Selling, general and administrative     10,704       8,458  
Total Costs and Expenses     33,012       32,690  
Income From Operations     9,132       10,507  
Other Expenses     (140 )     —   
Interest Expense     (38 )     (40 )
Investment Income     187       287  
Income Before Provision for Income Taxes and Noncontrolling Interests     9,141       10,754  
Provision for Income Taxes     (1,962 )     (2,039 )
Net Income     7,179       8,715  
Net Income - Noncontrolling Interests     (1,560 )     (2,313 )
Net Income – Attributable to FONAR   $ 5,619     $ 6,402  
Net Income Available to Common Stockholders   $ 5,281     $ 6,010  
Net Income Available to Class A Non-Voting Preferred Stockholders   $ 252     $ 292  
Net Income Available to Class C Common Stockholders   $ 86     $ 100  
Basic Net Income Per Common Share Available to Common Stockholders   $ 0.82     $ 0.93  
Diluted Net Income Per Common Share Available to Common Stockholders   $ 0.80     $ 0.92  
Basic and Diluted Income Per Share – Class C Common   $ 0.23     $ 0.26  
Weighted Average Basic Shares Outstanding – Common Stockholders     6,456       6,440  
Weighted Average Diluted Shares Outstanding - Common Stockholders     6,584       6,568  
Weighted Average Basic and Diluted Shares Outstanding – Class C Common     383       383  

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Amounts and shares in thousands, except per share amounts)(UNAUDITED)
     
    FOR THE SIX MONTHSENDED DECEMBER 31,
    2020   2019
Cash Flows from Operating Activities:                
Net income   $ 7,179     $ 8,715  
Adjustments to reconcile net income to net cash provided by operating activities:                
Depreciation and amortization     2,009       2,003  
Amortization on right-of-use assets     1,922       1,656  
Provision(Recovery) for bad debts     2,825       (978 )
Deferred income tax – net     1,962       1,816  
Compensatory element of stock issuances     83        
Stock issued for costs and expenses     1,941       1,990  
Abandoned patents     1        
(Increase) decrease in operating assets, net:                
Accounts, medical and management fee receivable(s)     (5,549 )     (4,300 )
Notes receivable     25       11  
Costs and estimated earnings in excess of billings on uncompleted contracts           372  
Inventories     (195 )     47  
Income tax receivable     671        
Prepaid expenses and other current assets     452       330  
Other assets     (1 )     (45  
Increase (decrease) in operating liabilities, net:                
Accounts payable     233       (576 )
Other current liabilities     (2,748 )     430  
Operating lease liabilities     (1,657 )     (1,447 )
Financing lease liabilities     24       —    
Customer deposits     378       28  
Billings in excess of costs and estimated earnings on uncompleted contracts     —        12  
Other liabilities     (3 )     123  
Net cash provided by operating activities     9,552       10,187  
Cash Flows from Investing Activities:                
Purchases of property and equipment     (2,143 )     (4,656 )
Purchase of short term investment     —         (199 )
Cost of patents     (90 )     (62 )
Net cash used in investing activities     (2,233 )     (4,917 )
Cash Flows from Financing Activities:                
Repayment of borrowings and capital lease obligations     (35 )     (24 )
Proceeds from debt     63       —    
Distributions to noncontrolling interests     (3,570 )     (3,735 )
Net cash used in financing activities     (3,542 )     (3,759 )
Net Increase in Cash and Cash Equivalents     3,777       1,511  
Cash and Cash Equivalents - Beginning of Period     36,802       13,882  
Cash and Cash Equivalents - End of Period   $ 40,579     $ 15,393  

 

Contact: Daniel Culver
Director of Communications
E-mail: investor@fonar.com
www.fonar.com
Phone: (631) 694-2929
Fax: (631) 390-1772